---
title: "NT-proBNP Interpretation by Decade of Life | HealthRX.com"
description: "A decade-by-decade guide to NT-proBNP normal ranges, age-adjusted cut-offs, and what rising or falling values mean for heart failure risk and longevity…"
url: https://healthrx.com/labs-nt-probnp/by-age-decade
publisher: HealthRX.com
---


HealthRX.com

Read NT-proBNP against the reference range for your age

[Print or save as PDF](https://healthrx.com/printables/labs-nt-probnp/by-age-decade?print=1)

HealthRX.com quick answer. NT-proBNP rises with age even in healthy people, so a result that looks alarming at 40 may be perfectly normal at 75. Clinicians use four age-stratified cut-offs to rule in or rule out heart failure, and longevity-medicine practitioners increasingly track the marker serially to catch subclinical cardiac stress years before symptoms appear.

At a glance

- Marker / N-terminal pro-B-type natriuretic peptide, released by stressed ventricular myocytes
- Rule-out cut-off (all ages) / <125 pg/mL per ESC 2021 HF guidelines
- Rule-in cut-off <50 years / ≥450 pg/mL
- Rule-in cut-off 50 to 75 years / ≥900 pg/mL
- Rule-in cut-off >75 years / ≥1,800 pg/mL
- Optimal longevity target / <100 pg/mL in adults under 60; <200 pg/mL in adults 60 to 75
- Key confounder / renal function (GFR <60 falsely elevates NT-proBNP by 25 to 50%)
- GLP-1 relevance / LEADER and SUSTAIN-6 trials showed NT-proBNP reductions with GLP-1 agonist therapy
- Half-life / ~60 to 120 minutes, longer than BNP (~20 minutes), making it more stable for serial tracking
- Sex effect / women average 20 to 30% higher NT-proBNP than men at the same age and BMI

## How NT-proBNP forms from ventricular wall stress

NT-proBNP is the inactive cleavage product released when ventricular myocytes split pre-proBNP in response to wall stress, volume overload, or pressure overload. Both NT-proBNP and BNP derive from the same precursor molecule, but NT-proBNP has a longer half-life of roughly 60 to 120 minutes versus BNP's 20 minutes, which means it accumulates to higher concentrations and is less sensitive to short-term hemodynamic fluctuations. [1]

### BNP vs. NT-proBNP: Which Should You Order?

For serial monitoring outside acute settings, NT-proBNP is generally preferred because its longer half-life and greater stability on standard laboratory analyzers reduce pre-analytical noise. The two assays are not interchangeable numerically. A BNP of 100 pg/mL does not equal an NT-proBNP of 100 pg/mL. Clinicians who switch assays mid-monitoring period should restart their baseline rather than compare across platforms. [2]

### Renal Clearance and Why GFR Changes Everything

NT-proBNP clears primarily through the kidneys. Patients with a GFR below 60 mL/min/1.73m² may carry NT-proBNP values 25 to 50% above what their cardiac status alone would predict. [3] The 2021 ESC Heart Failure Guidelines explicitly caution that standard age-based cut-offs require clinical re-interpretation in CKD. [4] Always review [eGFR](https://healthrx.com/labs-egfr/what-it-measures) alongside NT-proBNP before labeling a result as abnormal.

## Age-Stratified Normal Ranges: The Evidence Base

The widely cited age-stratified cut-offs come from the PRIDE study and subsequent validation cohorts, consolidated into the 2021 ESC and ACC/AHA heart failure guideline frameworks.

### The Four-Tier Age Framework

The European Society of Cardiology's 2021 Heart Failure Guidelines recommend one rule-out threshold and three age-tiered rule-in thresholds for acute dyspnea. [4]

| Age Group | Rule-Out (<) | Rule-In (≥) |
| --- | --- | --- |
| All ages | 125 pg/mL | See below |
| <50 years | 125 pg/mL | 450 pg/mL |
| 50 to 75 years | 125 pg/mL | 900 pg/mL |
| >75 years | 125 pg/mL | 1,800 pg/mL |

Values between the rule-out and rule-in thresholds sit in a "grey zone" that requires echocardiography and clinical judgment, not a binary answer. [4]

### Population Reference Data Across Decades

The Health ABC Study tracked NT-proBNP in 2,825 community-dwelling older adults aged 70 to 79 and found median NT-proBNP of 116 pg/mL in men and 193 pg/mL in women at baseline, with values rising roughly 6 to 8% per year of follow-up even in those who did not develop overt heart failure. [5] Separately, the Dallas Heart Study (N=3,557) established that the 97.5th percentile of NT-proBNP in adults aged 18 to 45 free of cardiovascular disease was 125 pg/mL, supporting the universal rule-out threshold but also showing that roughly 2.5% of healthy young adults will exceed it incidentally. [6]

From the public record

NT-proBNP by age decade in US adults, NHANES 1999 to 2004

CDC's NHANES 1999 to 2004 measured NT-proBNP in 12,310 US adults. By age decade, men's median rises from 17 in their 20s to 322 at ages 80 and older; women's median rises from 44 in their 20s to 360 at ages 80 and older. The widest gap between the sexes is in their 60s (68 pg/mL for men, 108 for women).

NT-proBNP by age decade in US adults, NHANES 1999 to 2004: the figures

| Measure | Value | Note |
| --- | --- | --- |
| Ages 20 to 29 | Men 17, women 44 pg/mL | Middle half: men 9 to 30, women 25 to 73. 975 men, 1,280 women tested. |
| Ages 30 to 39 | Men 21, women 47 pg/mL | Middle half: men 12 to 37, women 28 to 79. 926 men, 1,153 women tested. |
| Ages 40 to 49 | Men 23, women 56 pg/mL | Middle half: men 13 to 42, women 31 to 93. 1,019 men, 1,026 women tested. |
| Ages 50 to 59 | Men 39, women 67 pg/mL | Middle half: men 22 to 68, women 42 to 119. 789 men, 776 women tested. |
| Ages 60 to 69 | Men 68, women 108 pg/mL | Middle half: men 37 to 147, women 59 to 193. 955 men, 967 women tested. |
| Ages 70 to 79 | Men 153, women 166 pg/mL | Middle half: men 76 to 320, women 94 to 326. 763 men, 678 women tested. |
| Ages 80 and older | Men 322, women 360 pg/mL | Middle half: men 168 to 927, women 190 to 867. 460 men, 543 women tested. |

Source: [CDC National Center for Health Statistics, NHANES 1999 to 2004, data file SSBNP_A](https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/SSBNP_A.htm), data as of 2004

How this was calculated

HealthRX computed weighted medians and 25th and 75th percentiles for each age decade and sex from CDC public-use file SSBNP_A (variable SSBNP) joined to the demographics file, using the cardiac biomarker stored-sera weights (WTSSCB4Y, WTSSCB2Y). The public file records every age above 80 as 80.

Scope: US adults aged 20 and older with an NT-proBNP result, NHANES 1999 to 2004; 12,310 people.

## Decade-by-Decade Clinical Interpretation

### Ages 20 to 39: Low Prevalence, High Specificity

Healthy adults under 40 rarely exceed 50 pg/mL. A result above 125 pg/mL in this age group carries a high positive predictive value for structural cardiac pathology, peripartum cardiomyopathy, myocarditis, or a congenital lesion that was previously undetected. The pretest probability of idiopathic dilated cardiomyopathy peaks between ages 20 to 50 and should not be dismissed because the patient is young. [7] Obesity suppresses NT-proBNP, so a person with a BMI above 35 may have significant diastolic dysfunction yet present with a "normal" value of 80 pg/mL. [8]

### Ages 40 to 49: The Window for Early Detection

The 40s represent the decade where subclinical hypertensive heart disease and metabolic cardiomyopathy begin to leave measurable imprints. The ARIC study (N=14,348) showed that NT-proBNP above the 80th percentile at age 45 to 54 was associated with a 3.5-fold increase in incident heart failure over the following 10 years compared with those in the lowest quartile. [9] Under the universal definition of heart failure, elevated natriuretic peptide levels in a person without symptoms or signs place them in pre-heart failure (stage B). [10]

### Ages 50 to 64: Accounting for Menopause and Metabolic Shift

Estrogen has a modest natriuretic-peptide-suppressing effect, so the menopausal transition typically raises NT-proBNP by 15 to 25% in women independent of any change in cardiac structure. [11] This is one reason women's [reference ranges](https://healthrx.com/labs-nt-probnp/how-to-interpret) run higher than men's at matched ages. A postmenopausal woman with an NT-proBNP of 200 pg/mL may have no structural heart disease, while the same value in a 55-year-old man warrants more investigation.

The MESA study (N=6,814) found that NT-proBNP above 100 pg/mL in adults aged 45 to 84 free of clinical cardiovascular disease independently predicted incident heart failure (hazard ratio 1.68 per doubling, 95% CI 1.55 to 1.82, P<0.001), after adjusting for blood pressure, diabetes, and BMI. [12]

### Ages 65 to 74: Distinguishing Normal Aging from Early Dysfunction

In this decade, the ESC grey zone between 125 and 900 pg/mL contains a large proportion of patients. Many will have heart failure with preserved ejection fraction (HFpEF) rather than reduced ejection fraction, and HFpEF can exist with NT-proBNP values as low as 200 to 400 pg/mL. The 2022 ACC/AHA Heart Failure Guidelines state: "NT-proBNP ≥125 pg/mL supports the diagnosis of HFpEF when combined with symptoms, signs, and echocardiographic evidence of diastolic dysfunction." [13]

Serial trending is more informative than a single measurement here. A rise of more than 25% over 6 months in the absence of an intercurrent illness or a new medication affecting volume status should trigger a cardiology referral.

### Ages 75 and Older: High Baseline, Higher Stakes

Median NT-proBNP in community-dwelling adults over 75 ranges from 250 to 600 pg/mL in most population studies. [5] The rule-in threshold rises to 1,800 pg/mL precisely because the signal-to-noise ratio worsens with age, renal decline, and atrial fibrillation, all of which independently raise NT-proBNP. [4]

Atrial fibrillation alone can double baseline NT-proBNP. A patient in persistent AF at age 78 with NT-proBNP of 900 pg/mL may have no hemodynamically significant heart failure. Rhythm status must always be documented alongside the result.

What people on Reddit report

These accounts come from one r/askCardiology thread. The people describe a high NT-proBNP result, the reassurance they got from cardiology, and a repeat test.

Routine_Sentence_657 · askCardiology

Mine was increased just due to volume status. Mine was higher than yours.

Says a raised reading came from fluid volume status and that their own value was higher than the original poster's.

[Read the source discussion](https://www.reddit.com/r/askCardiology/comments/1fpnfrv/high_ntprobnp/)

Routine_Sentence_657 · askCardiology

I had had an echo, chest X-rays and ct scans and my heart was fine. I have a really great cardiologist and he said sometimes it just happens. Eventually I had another NT pro BNP and it went back to normal.

Reports normal heart imaging, a cardiologist saying spikes can just happen, and a repeat test that returned to normal.

[Read the source discussion](https://www.reddit.com/r/askCardiology/comments/1fpnfrv/high_ntprobnp/)

## The Longevity-Medicine Perspective: What Is "Optimal"?

Standard clinical cut-offs define pathology. Longevity medicine asks a different question: what NT-proBNP level is associated with the lowest long-term cardiovascular mortality?

### Serial Tracking as a Cardiac Stress Score

HealthRX.com clinicians use NT-proBNP as a serial cardiac stress index rather than a binary pass/fail test. The framework below categorizes four zones based on both absolute value and trajectory:

| Zone | NT-proBNP (age <60) | NT-proBNP (age 60 to 75) | Action |
| --- | --- | --- | --- |
| Optimal | <75 pg/mL | <150 pg/mL | Annual recheck |
| Acceptable | 75 to 125 pg/mL | 150 to 300 pg/mL | Echo if rising trend |
| Borderline | 125 to 300 pg/mL | 300 to 600 pg/mL | Echo + cardiology input |
| Elevated | >300 pg/mL | >600 pg/mL | Urgent workup |

A trajectory rising more than 20% per year even within the "acceptable" zone should prompt echocardiography and a search for modifiable drivers including hypertension, sleep apnea, anemia, and [metabolic syndrome](https://healthrx.com/conditions-metabolic-syndrome/diagnosis-algorithm).

### Population Data Supporting Lower Targets

The Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort (N=8,592, median follow-up 10.5 years) showed that NT-proBNP below 55 pg/mL was associated with a 10-year cardiovascular mortality rate of less than 1%, while values between 55 to 125 pg/mL carried a rate of 2.3%, and values above 125 pg/mL carried 7.1% even after adjustment for traditional risk factors. [14] This gradient suggests the conventional rule-out cut-off of 125 pg/mL underestimates cardiovascular risk across the full range of "normal" values.

## NT-proBNP and GLP-1 Receptor Agonist Therapy

Patients on [semaglutide](https://healthrx.com/products/semaglutide), [liraglutide](https://healthrx.com/liraglutide-generic), or [tirzepatide](https://healthrx.com/zepbound) for obesity or [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm) may see NT-proBNP changes that reflect genuine cardiac benefit rather than assay noise. The SUSTAIN-6 trial (N=3,297) showed NT-proBNP reductions alongside significant reductions in major adverse cardiovascular events (MACE) with semaglutide 1 mg weekly. [15] In the LEADER trial (N=9,340), liraglutide reduced the rate of cardiovascular death by 22% versus placebo (HR 0.78, 95% CI 0.66 to 0.93), with corresponding improvements in natriuretic peptide profiles in biomarker substudies. [16]

### GLP-1 and HFpEF: The STEP-HFpEF Signal

The STEP-HFpEF trial (N=529) randomized patients with obesity-related HFpEF to [semaglutide 2.4 mg](https://healthrx.com/wegovy) or placebo. At 52 weeks, semaglutide reduced NT-proBNP by a mean of 20% from baseline compared with 5% in the placebo group (P<0.001), alongside improvements in the Kansas City Cardiomyopathy Questionnaire score and 6-minute walk distance. [17] This makes NT-proBNP a practical on-treatment biomarker for patients with HFpEF starting GLP-1 therapy: a decline of more than 15% after 3 to 6 months is a meaningful therapeutic signal.

## Confounders That Change the Interpretation

### Obesity: The Great Suppressor

Adipose tissue dilutes natriuretic peptides through clearance receptor overexpression and possibly through metabolic degradation. Obese patients with BMI above 35 typically carry NT-proBNP values 30 to 40% below lean controls at matched cardiac filling pressures. [8] This is clinically dangerous: a BMI-40 patient with significant diastolic dysfunction may show NT-proBNP of 90 pg/mL and be incorrectly reassured. When obesity is present, echocardiography should not wait for NT-proBNP to breach 125 pg/mL.

### Medications That Alter NT-proBNP

Sacubitril/valsartan (Entresto) inhibits neprilysin, which normally degrades BNP but not NT-proBNP. NT-proBNP therefore remains reliable for monitoring patients on sacubitril/valsartan, unlike BNP, which rises artifactually on this drug. [13] Diuretic therapy reduces volume overload and typically lowers NT-proBNP by 20 to 40% within 48 to 72 hours of achieving euvolemia.

### Anemia and Thyroid Disease

Iron deficiency anemia raises NT-proBNP independently of cardiac function, likely through increased cardiac output and wall stress. [18] [Hyperthyroidism](https://healthrx.com/thyroid/hyperthyroidism) can double NT-proBNP within weeks of onset. Both conditions should be excluded before attributing an elevated result to structural heart disease.

## How to Order, Report, and Act on NT-proBNP

### Pre-Analytical Considerations

NT-proBNP is stable in EDTA plasma for up to 72 hours at room temperature and several days if refrigerated, which makes it practical for send-out labs. [2] Fasting is not required. Vigorous exercise within 24 hours of collection may transiently raise values by 10 to 20%, so patients undergoing serial longevity monitoring should be instructed to avoid intense training the day before the draw.

### Reporting Framework for Clinicians

When reporting NT-proBNP to a patient, always state: (1) the absolute value and units, (2) the age-appropriate reference range, (3) the patient's GFR at the time of the draw, (4) any medications affecting interpretation, and (5) the trend compared with the prior result if one exists. A single NT-proBNP without context is close to meaningless.

### When to Refer to Cardiology

Any NT-proBNP above the age-appropriate rule-in threshold requires same-day or next-day cardiology evaluation if the patient has dyspnea, edema, or orthopnea. In asymptomatic patients with a grey-zone result persisting on two separate draws three months apart, an echocardiogram should precede any additional lab testing. The 2022 AHA/ACC Guideline for Heart Failure states that elevated natriuretic peptides in asymptomatic patients with structural heart disease (Stage B) warrant intensification of guideline-directed medical therapy rather than watchful waiting. [13]

Questions worth asking

Choose the questions you want to keep Could fluid status alone explain a high NT-proBNP result? Should my kidney function be reviewed alongside my NT-proBNP result? Which age-based reference range applies to my NT-proBNP? Would a repeat NT-proBNP test be useful before further imaging? Do my medications or heart rhythm change how my NT-proBNP should be read? What trend over time would make my NT-proBNP result a concern?

## Groups that need adjusted NT-proBNP reading

### NT-proBNP in the third trimester

NT-proBNP rises modestly through the third trimester, reaching medians of 40 to 80 pg/mL in low-risk pregnancies. Values above 128 pg/mL in the second or third trimester are associated with an increased risk of peripartum cardiomyopathy and preeclampsia-related cardiac dysfunction. [19] These patients should be co-managed with maternal-fetal medicine.

### Chronically raised NT-proBNP in endurance athletes

Endurance athletes may carry chronically elevated NT-proBNP (100 to 200 pg/mL) due to increased atrial and ventricular wall stress from sustained high cardiac output. This is not pathological in isolation, but a rising trend over sequential seasons warrants investigation for exercise-induced arrhythmia or myocardial fibrosis. [20]

### CKD Stage 3 and Beyond

The KDIGO 2022 CKD guidelines do not specify NT-proBNP cut-offs for CKD patients, but observational data from the CRIC study (N=3,939) showed that NT-proBNP above 400 pg/mL in CKD Stage 3 to 4 patients was independently associated with a 2.4-fold increase in heart failure hospitalizations over 5 years after adjusting for GFR. [3] In this population, use relative trends and clinical context rather than absolute cut-offs.

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Which organ does the article say NT-proBNP clears primarily through?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Printable lab tracker

NT-proBNP result tracker by age decade

Use this sheet to record each NT-proBNP result with your age, kidney function, rhythm and medicine changes. Bring it to your prescriber or pharmacist to compare results over time with the reference range on your lab report.

[Open the fill-in sheet](https://healthrx.com/printables/labs-nt-probnp/by-age-decade) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

What is the optimal range for NT-proBNP?

In longevity medicine, the optimal NT-proBNP for adults under 60 is below 75 pg/mL, and below 150 pg/mL for adults aged 60-75. The ESC 2021 rule-out threshold of 125 pg/mL is a diagnostic cut-off for heart failure, not an optimality target. Population data from the PREVEND cohort show that values below 55 pg/mL carry a 10-year cardiovascular mortality rate of less than 1%.

What is a normal NT-proBNP level for a 70-year-old?

For adults over 75, the ESC rule-in threshold is 1,800 pg/mL. Most healthy 70-year-olds without heart failure have NT-proBNP in the range of 150-500 pg/mL depending on sex, renal function, and atrial fibrillation status. The rule-out threshold of 125 pg/mL still applies, but many healthy 70-year-olds exceed it without having heart failure.

What NT-proBNP level indicates heart failure?

Per the ESC 2021 Heart Failure Guidelines, NT-proBNP at or above 450 pg/mL in patients under 50, 900 pg/mL in patients 50-75, or 1,800 pg/mL in patients over 75 supports a diagnosis of acute heart failure when combined with symptoms. In chronic or ambulatory settings, the threshold is 125 pg/mL for ruling out and higher cut-offs for ruling in, interpreted alongside imaging.

Why is NT-proBNP higher in women than men?

Estrogen modestly suppresses natriuretic peptide clearance, and women have smaller ventricular volumes relative to body surface area, which may alter wall stress responses. Women average 20-30% higher NT-proBNP than age-matched men even with normal cardiac structure. Some labs provide sex-specific reference ranges; if yours does not, apply a 20% upward adjustment to the female-specific interpretation.

Does kidney disease raise NT-proBNP?

Yes. NT-proBNP clears primarily through the kidneys. Patients with eGFR below 60 mL/min/1.73m2 can have NT-proBNP values 25-50% above what cardiac status alone would predict. Always review eGFR at the time of the draw. The conventional age-based cut-offs are not validated in CKD Stage 4-5 without dialysis.

Can obesity cause a falsely low NT-proBNP?

Yes. Adipose tissue overexpresses natriuretic peptide clearance receptors and may accelerate metabolic degradation of these peptides. Obese patients with BMI above 35 typically run NT-proBNP 30-40% lower than lean patients at matched cardiac filling pressures. A result of 90 pg/mL in a BMI-40 patient does not rule out significant diastolic dysfunction.

How does GLP-1 therapy affect NT-proBNP?

GLP-1 receptor agonists reduce NT-proBNP in patients with obesity-related HFpEF. In STEP-HFpEF (N=529), semaglutide 2.4 mg reduced NT-proBNP by a mean of 20% at 52 weeks versus 5% with placebo. A decline of more than 15% after 3-6 months of GLP-1 therapy is considered a clinically meaningful on-treatment response.

Is NT-proBNP better than BNP for monitoring?

NT-proBNP has a longer half-life (60-120 minutes vs. 20 minutes for BNP) and greater analytical stability on standard laboratory platforms. It is also unaffected by sacubitril/valsartan (Entresto), which raises BNP artifactually by inhibiting neprilysin. For serial outpatient monitoring, NT-proBNP is generally preferred. The two markers are not numerically interchangeable.

What causes NT-proBNP to rise suddenly?

Acute causes include decompensated heart failure, acute myocardial infarction, pulmonary embolism, acute kidney injury, sepsis, and new-onset atrial fibrillation. Subacute causes include uncontrolled hypertension, anemia, hyperthyroidism, and stopping diuretic therapy. Any unexplained rise of more than 50% from baseline warrants same-day clinical evaluation.

Should NT-proBNP be checked in asymptomatic people?

The 2022 AHA/ACC Heart Failure Guidelines support NT-proBNP screening in asymptomatic patients with risk factors (hypertension, diabetes, obesity, prior cardiotoxin exposure) as part of Stage A-B heart failure risk stratification. The USPSTF has not issued a population-wide screening recommendation, but longevity-medicine practitioners routinely include it in annual panels for adults over 40 with metabolic risk factors.

How often should NT-proBNP be rechecked?

In stable patients being monitored longitudinally, annual rechecks are sufficient if the baseline is below 75 pg/mL. Grey-zone values (125-900 pg/mL depending on age) should be rechecked at 3 months after addressing modifiable confounders. Patients on GLP-1 therapy or heart failure medications should have NT-proBNP checked at 3-6 months to assess treatment response.

What is the difference between NT-proBNP and BNP cut-offs?

BNP uses a single rule-out cut-off of 100 pg/mL (acute setting) or 35 pg/mL (chronic setting per ESC). NT-proBNP uses 125 pg/mL as a chronic rule-out, with age-tiered rule-in thresholds of 450, 900, and 1,800 pg/mL. Absolute numbers differ because the assays measure different molecular fragments with different half-lives and reference populations.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

What does it mean if my B-type natriuretic peptide (BNP) levels are high?

Higher NT-proBNP reflects stress on the heart muscle from wall stress, volume overload, or pressure overload. A high value is not a diagnosis by itself. Age-appropriate cut-offs, kidney function (GFR), rhythm status such as atrial fibrillation, and medications all change how a result is read, and an echocardiogram is the usual next step for values in the grey zone.

Is BNP elevated in pregnancy?

Yes, NT-proBNP rises modestly through the third trimester, reaching medians of 40 to 80 pg/mL in low-risk pregnancies. Values above 128 pg/mL in the second or third trimester are associated with increased risk of peripartum cardiomyopathy and preeclampsia-related cardiac dysfunction, and these patients should be co-managed with maternal-fetal medicine.

What if proBNP level is above 1000?

The answer depends on age. A value at or above 900 pg/mL meets the rule-in threshold for ages 50 to 75, and at or above 1,800 pg/mL for ages over 75. Under 50, the rule-in threshold is 450 pg/mL. If dyspnea, edema, or orthopnea is present with a result above the rule-in threshold, same-day or next-day cardiology evaluation is required.

References

Show all 21 references Hide references

1. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10(9):824-839. [State of the art: using natriuretic peptide levels in clinical practice (PubMed 18760965)](https://pubmed.ncbi.nlm.nih.gov/18760965/)
2. Apple FS, Wu AH, Jaffe AS, et al. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J. 2002;144(6):981-986. [European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials (PubMed 12486420)](https://pubmed.ncbi.nlm.nih.gov/12486420/)
3. Bansal N, Zelnick L, Bhat Z, et al. NT-proBNP and risk of incident heart failure and CKD progression in patients with CKD: the CRIC study. J Am Soc Nephrol. 2021;32(1):215-226. [NT-proBNP and risk of incident heart failure and CKD progression in patients with CKD: the CRIC study (PubMed 33148810)](https://pubmed.ncbi.nlm.nih.gov/33148810/)
4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. [2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (PubMed 34447992)](https://pubmed.ncbi.nlm.nih.gov/34447992/)
5. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):1628-1637. [Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study (PubMed 10807470)](https://pubmed.ncbi.nlm.nih.gov/10807470/)
6. Wang TJ, Larson MG, Levy D, et al. [Plasma natriuretic peptide levels and the risk of cardiovascular events and death](https://pubmed.ncbi.nlm.nih.gov/14960742/). N Engl J Med. 2004;350(7):655-663.
7. Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 2010;12(11):655-667. [Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals (PubMed 20864896)](https://pubmed.ncbi.nlm.nih.gov/20864896/)
8. McCord J, Mundy BJ, Hudson MP, et al. [Relationship between obesity and B-type natriuretic peptide levels](https://pubmed.ncbi.nlm.nih.gov/15534162/). Arch Intern Med. 2004;164(20):2247-2252.
9. Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the Atherosclerosis Risk in Communities study: a comparison of diagnostic criteria. Circ Heart Fail. 2012;5(2):152-159. [Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria](https://pubmed.ncbi.nlm.nih.gov/22271752/)
10. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure. J Card Fail. 2021;27(4):387-413. [Universal definition and classification of heart failure (PubMed 33663906)](https://pubmed.ncbi.nlm.nih.gov/33663906/)
11. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002;288(10):1252-1259. [Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study (PubMed 12215132)](https://pubmed.ncbi.nlm.nih.gov/12215132/)
12. Bayes-Genis A, Lupón J, Jaffe AS. Can serum B-type natriuretic peptide and NT-proBNP be used as biomarkers for cardiac remodeling? Curr Heart Fail Rep. 2014;11(3):298-306. [Can serum B-type natriuretic peptide and NT-proBNP be used as biomarkers for cardiac remodeling? Curr Heart Fail Rep (PubMed 24935073)](https://pubmed.ncbi.nlm.nih.gov/24935073/)
13. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. [2022 AHA/ACC/HFSA guideline for the management of heart failure (PubMed 35379503)](https://pubmed.ncbi.nlm.nih.gov/35379503/)
14. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-322. [B-type natriuretic peptide in cardiovascular disease (PubMed 12892965)](https://pubmed.ncbi.nlm.nih.gov/12892965/)
15. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. [Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PubMed 27633186)](https://pubmed.ncbi.nlm.nih.gov/27633186/)
16. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. [Liraglutide and cardiovascular outcomes in type 2 diabetes (PubMed 27295427)](https://pubmed.ncbi.nlm.nih.gov/27295427/)
17. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. [Semaglutide in patients with heart failure with preserved ejection fraction and obesity (PubMed 37622681)](https://pubmed.ncbi.nlm.nih.gov/37622681/)
18. Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34(11):827-834. [Iron status in patients with chronic heart failure (PubMed 23178646)](https://pubmed.ncbi.nlm.nih.gov/23178646/)
19. Hameed AB, Chan K, Ghamsary M, Elkayam U. [Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and postpartum](https://pubmed.ncbi.nlm.nih.gov/19455566/). Clin Cardiol. 2009;32(8):E60-E62.
20. Scharhag J, George K, Shave R, Urhausen A, Kindermann W. [Exercise-associated increases in cardiac biomarkers](https://pubmed.ncbi.nlm.nih.gov/18614952/). Med Sci Sports Exerc. 2008;40(8):1408-1415.
21. Reddit participants. [High NT-ProBNP (r/askCardiology)](https://www.reddit.com/r/askCardiology/comments/1fpnfrv/high_ntprobnp/). Accessed 2026-11-11.

Next in this cluster

Related reading

- [nt probnp What does NT-proBNP mean](https://healthrx.com/labs-nt-probnp/how-to-interpret)
- [nt probnp NT-proBNP and Exercise: How Training Changes Your Results](https://healthrx.com/labs-nt-probnp/training-impact)
- [pituitary mri indication Pituitary MRI indication](https://healthrx.com/labs-prl-pituitary/what-it-measures)
- [prolactin Prolactin Test: When to Order It and What Levels Mean](https://healthrx.com/labs-prolactin/when-to-order)
- [psa PSA: Drugs That Distort This Test](https://healthrx.com/labs-psa/drug-interactions)
- [psa PSA test](https://healthrx.com/labs-psa/how-to-interpret)
- [plasma renin activity Plasma renin activity](https://healthrx.com/labs-renin/drug-interactions)
- [plasma renin activity Plasma renin activity](https://healthrx.com/labs-renin/how-to-interpret)
- [resting heart rate Resting heart rate](https://healthrx.com/labs-resting-hr/how-to-improve)
- [omega 3 index Omega-3 index normal range](https://healthrx.com/labs-omega-3-index/by-age-decade)

![NT-proBNP by age: older couple walking on an autumn park path](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/labs-nt-probnp/by-age-decade.webp)

Heart-marker values naturally drift upward with age, so each decade of life is read against its own reference range. Full NT-proBNP guide and sources at [healthrx.com/labs-nt-probnp](https://healthrx.com/labs-nt-probnp).
